Axial Biotech Aims to Predict Scoliosis Progression With DNA Test
Adolescent idiopathic scoliosis tends to run in families, but determining which patients will develop severe spinal curvature is an inexact science.
diagnostics
A Busy Year for HydraDx
The economy is tough for biotech start-ups, but the CEO of HydraDx is feeling confident.
Cantimer’s Portable Devices Keep It Simple
The company’s key product is a portable hydration monitor that can gauge an individual’s level of hydration from a drop of saliva in approximately one minute.
[OneMedForum] Clarient Grows Along with Cancer Testing Market
The Aliso Viejo, Calif.-based company achieved several major milestones in 2009.
Chembio Diagnostics at the 2010 OneMedForum
Lawrence A. Siebert, President and CEO of Chembio Diagnostics, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
Clarient, Inc. at the 2010 OneMedForum
Ron Andrews, CEO of Clarient, Inc., discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
Strategic Medicine at the 2010 OneMedForum
Michael N. Liebman, President and Managing Director of Strategic Medicine, discusses his company with OneMedTV correspondent Alicia Ontiveros at the 2010 OneMedForum in San Francisco.
[OneMedForum] Biomoda’s Platform for Early Cancer Detection
Biomoda’s CyPath diagnostic assay is based on molecular marker technology originally developed at the Los Alamos National Laboratory.
Clarient Acquires AGI In All-Stock Merger
Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
[Company Profile] MicroPhage
MicroPhage of Longmont, Colo., has developed a platform of rapid diagnostic tests to identify staph bacteria and determine methicillin resistance (MRSA) and susceptibility (MSSA).